1192322-60-3Relevant academic research and scientific papers
Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition and kit for inhibiting the growth of cancer containing the same as an active ingredient
-
, (2021/07/20)
The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutical composition and a kit containing same as an active ingredient. The disubstituted adamantyl derivative according to the present invention suppresses the growth of cancer cells by targeting mitochondria ETC complex I and damaging the metabolism of cancer cells, and thus can be useful as an anticancer pharmaceutical composition that is a powerful therapeutic agent for cancer dependent on oxidative phosphorylation for producing ATP.
A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives
Min, Kyung Hoon,Xia, Yan,Kim, Eun Kyung,Jin, Yinglan,Kaur, Navneet,Kim, Eun Seon,Kim, Dae Kyong,Jung, Hwa Young,Choi, Yongseok,Park, Mi-Kyung,Min, Yong Ki,Lee, Kiho,Lee, Kyeong
scheme or table, p. 5376 - 5379 (2010/05/19)
Novel disubstituted adamantyl derivatives were synthesized and evaluated in a P-glycoprotein dependent multidrug resistance cancer cell line. The hit to lead optimization provided potent MDR reversal agents. Some potent adamantyl derivatives were more than 10-fold more potent than verapamil without considerable intrinsic cytotoxicity. The 3-trifluorophenyl derivative 14f did not affect the metabolism of CYP450 3A4, whereas most of MDR revertants had a weak inhibitory effect.
